Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$1.97 - $5.41 $1.45 Million - $3.99 Million
-738,201 Reduced 74.57%
251,727 $508,000
Q3 2022

Nov 14, 2022

BUY
$12.03 - $14.22 $11.9 Million - $14.1 Million
989,928 New
989,928 $14 Million

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $78.4M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.